9999999997-18-007842.txt : 20180913 9999999997-18-007842.hdr.sgml : 20180913 20180912185127 ACCESSION NUMBER: 9999999997-18-007842 CONFORMED SUBMISSION TYPE: CT ORDER PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20180913 DATE AS OF CHANGE: 20180912 ACTION DATE: 20180913 RECEIVED DATE: 20180912 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Dicerna Pharmaceuticals Inc CENTRAL INDEX KEY: 0001399529 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CT ORDER SEC ACT: 1934 Act SEC FILE NUMBER: 001-36281 FILM NUMBER: 181067640 BUSINESS ADDRESS: STREET 1: 87 CAMBRIDGEPARK DRIVE CITY: CAMBRIDGE STATE: MA ZIP: 02140 BUSINESS PHONE: 617 621 8097 MAIL ADDRESS: STREET 1: 87 CAMBRIDGEPARK DRIVE CITY: CAMBRIDGE STATE: MA ZIP: 02140 CT ORDER 1 filename1.pdf begin 644 filename1.pdf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